Hepatitis B virus DNA viral load determination in hepatitis B surface antigen-negative Swiss blood donors

Transfusion

Volumn 54, Issue 11, 2014, Pages 2961-2967

  Stolz, Martin ^a   Tinguely, Caroline ^a   Fontana, Stefano ^a   Niederhauser, Christoph ^a  

^a Blood Transfusion Service SRC Berne   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD DONOR; DNA DETERMINATION; ELISA KIT; FEMALE; HEMATOLOGY ANALYZER; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B VIRUS NUCLEIC ACID TEST; HUMAN; IMMUNOASSAY; IMMUNOASSAY ANALYZER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; QUANTITATIVE ANALYSIS; SWISS; VIRUS DETECTION; VIRUS LOAD; BLOOD; DONOR SELECTION; IMMUNOLOGY; NUCLEIC ACID AMPLIFICATION; RETROSPECTIVE STUDY; SWITZERLAND;

BLOOD DONORS; DNA, VIRAL; DONOR SELECTION; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RETROSPECTIVE STUDIES; SWITZERLAND; VIRAL LOAD;

EID: 84912109740     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12694     Document Type: Article

References (41)

1. Stebler C, Infanti L, Eiche B, et al. Prevalence of anti-HBc antibodies in Swiss blood donors, a 4 month survey at the Blood Transfusion Centre Basel. ISBT Congress 2006 Cape Town.
2. Niederhauser C, Graziani M, Stolz M, et al. Blood donor screening: how to decrease the risk of transfusion transmitted hepatitis B virus?. Swiss Med Wkly 2008; 138: 134-141.
3. Stolz M, Tinguely C, Graziani M, et al. Efficacy of individual nucleic acid amplification testing in reducing the risk of transfusion-transmitted hepatitis B virus infection in Switzerland, a low endemic region. Transfusion 2010; 50: 2695-2706.
4. Jilg W, Sieger E, Zachoval R, et al. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol 1995; 23: 14-20.
5. Cardoso MS, Koerner K, Kubanek B,. Mini-pool screening by nucleic acid testing for hepatitis B virus, hepatitis C virus and HIV: preliminary results. Transfusion 1998; 38: 905-907.
6. Tomono T, the Japanese Red Cross NAT Screening Research Group. Status of NAT screening for HCV, HIV and HBV: experience in Japan. In:, Brown F, Seitz R, editors. Advances in transfusion safety. Developments in biologicals. Greenport (NY): Verlag Karger; 2002. p. 29-39.
7. Sato S, Ohhashi W, Ihara H, et al. Comparison of the sensitivity of NAT using pooled donor samples for HBV and that of a serologic HBsAg assay. Transfusion 2001; 41: 1107-1113.
8. Roth WK, Weber M, Petersen D, et al. NAT for HBV and anti-HBC testing increase blood safety. Transfusion 2002; 42: 869-875.
9. Minegishi K, Yoshikawa A, Kishimoto S, et al., Japanese Red Cross NAT Screening Research Group. Superiority of minipool nucleic acid amplification technology for hepatitis B virus over chemiluminescence immunoassay for hepatitis B surface antigen screening. Vox Sang 2003; 84: 287-291.
10. Vermeulen M, Lelie N, Sykes W, et al. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion 2009; 49: 1115-1125.
11. Allain JP,. Occult hepatitis B infection: implication in transfusion. Vox Sang 2004; 86: 83-91.
12. Hoolinger FB,. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 2008; 48: 1001-1026.
13. Busch MP,. Prevention of transmission of hepatitis B, hepatitis C and human immunodeficiency virus infections through blood transfusion by anti-HBc testing. Vox Sang 1998; 74 (Suppl 2): 147-154.
14. Dodd RY, Reesink HW, Busch MP, et al. ISBT International Forum: do surrogate tests improve the safety of the blood supply? Vox Sang 1995; 69: 280-291.
15. Antar W, El-Shokry MH, Abd El Hamid WA, et al. Significance of detecting anti-HBc among Egyptian male blood donors negative for HBsAg. Transfus Med 2010; 20: 409-413.
16. Allain JP, Mihaljevic I, Gonzalez-Fraile MI, et al. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion 2013; 53: 1405-1415.
17. Glynn SA, Kleinma SH, Wright DJ, et al. for the REDS Group. International application of the incidence rate/WP model. Transfusion 2002; 42: 966-972.
18. Michalak TI, Pasquinelli C, Guilhot S, et al. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 94: 907. Erratum for J Clin Invest 1994;93:230-9.
19. Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-1108.
20. Weber B,. The diagnostic and clinical impact of the genetic variability of the S (surface) gene of hepatitis B virus. J Lab Med 2004; 28: 56-59.
21. Yotsuyanagi H, Yasuda K, Iino S, et al. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 1998; 27: 1377-1382.
22. Penna A, Artini M, Cavalli A, et al. Long-lasting memory T cell response following self-limited acute hepatitis B. J Clin Invest 1996; 98: 1185-1194.
23. Brechot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001; 34: 194-203.
24. Alhababi F, Sallam TA, Tong CY,. The significance of anti-HBc only in the clinical virology laboratory. J Clin Virol 2003; 27: 162-169.
25. Dreier J, Kröger M, Diekmann J, et al. Low-level viraemia of hepatitis B virus in an anti-HBc- and anti-HBs-positive blood donor. Transfus Med 2004; 14: 97-103.
26. Kleinman SH, Kuhns MC, Todd DS, et al. for the Retrovirus Epidemiology Donor Study. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 2003; 43: 696-704.
27. Busch MP,. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? Transfus Clin Biol 2004; 11: 26-32.
28. Kleinman S, Strong DM, Tegmeier G, et al. Hepatitis B (HBV) DNA screening of blood donation in minipools with the Cobas AmpliScreen HBV test. Transfusion 2005; 45: 1247-1257.
29. Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003; 43: 788-798.
30. Matsumoto C, Tadokoro K, Fujimura K, et al. Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion 2001; 41: 878-884.
31. Brojer E, Grabarczyk P, Liszewski G, et al., Polish Blood Transfusion Service Viral Study Group. Characterization of hepatitis B virus DNA positive/hepatitis B surface antigen-negative blood donors identified in the Polish NAT screening program. Hepatology 2006; 44: 1666-1674.
32. Dow BC, Peterkin MA, Green RH, et al. Hepatitis B virus transmission by blood donation negative for hepatitis B surface antigen, antibody to HBsAg, antibody to hepatitis core antigen and HBV DNA. Vox Sang 2001; 81: 140.
33. Manzini P, Girotto M, Borsotti R, et al. Italian blood donors with anti-HBc and occult hepatitis B virus infection. Haematologica 2007; 92: 1664-1670.
34. Manzini P, Abate ML, Valpreda C, et al. Evidence of acute primary occult hepatitis B virus infection in an Italian repeat blood donor. Transfusion 2009; 49: 757-764.
35. Niederhauser C, Weingand T, Candotti D, et al. Fatal outcome of a hepatitis B virus transfusion-transmitted infection. Vox Sang 2010; 98: 504-507.
36. Servant-Delmas A, Chuteau C, Lefort C, et al. Two cases of transfusion-transmitted heptatitits B virus (HBV) infection in a low-endemic country before implementaition of HBV nucleic acid testing. Transfusion 2013; 53: 291-296.
37. Satake M, Taira R, Yugi H, et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007; 47: 1197-1205.
38. Taira R, Satake M, Momose S, et al. Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan. Transfusion 2013; 53: 1393-1404.
39. Vermeulen M, Dickens C, Lelie N, et al. B virus transmission by blood transfusion during 4 years of hepatitis individual-donation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion 2012; 52: 880-892.
40. Tsoi WC, Lelie N, Lin CK,. Enhanced detection of hepatitis B virus in Hong Kong blood donors after introduction of a more sensitive transcription-mediated amplification assay. Transfusion 2013; 53 (10 Pt 2): 2477-2488.
41. Stramer SL, Krysztof DE, Brodsky JP, et al. Comparative analysis of triplex nucleic acid test assays in United States blood donors. Transfusion 2013; 53 (10 Pt 2): 2525-2537.